And Gilead seems to be edging away from its partner.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
The company will start a phase 2/3 trial of PF-08634404 in March.
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
